Perspective Therapeutics/$CATX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Perspective Therapeutics
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Ticker
$CATX
Sector
Primary listing
AMEX
Industry
Biotechnology
Headquarters
Employees
139
ISIN
US46489V3024
CATX Metrics
BasicAdvanced
$307M
-
-$1.21
1.13
-
Price and volume
Market cap
$307M
Beta
1.13
52-week high
$16.55
52-week low
$1.60
Average daily volume
1.3M
Financial strength
Current ratio
17.016
Quick ratio
16.703
Long term debt to equity
0.978
Total debt to equity
1.341
Interest coverage (TTM)
-514.45%
Profitability
EBITDA (TTM)
-72.949
Gross margin (TTM)
-3,005.03%
Net profit margin (TTM)
-5,790.07%
Operating margin (TTM)
-5,140.99%
Effective tax rate (TTM)
2.42%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-15.56%
Return on equity (TTM)
-32.92%
Valuation
Price to revenue (TTM)
196.92
Price to book
1.07
Price to tangible book (TTM)
1.3
Price to free cash flow (TTM)
-2.793
Free cash flow yield (TTM)
-35.81%
Free cash flow per share (TTM)
-147.89%
Growth
Revenue change (TTM)
-3.60%
Earnings per share change (TTM)
-30.52%
What the Analysts think about CATX
Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
Bulls say / Bears say
Interim Phase 1/2a results of [212Pb]VMT-α-NET presented at ASCO showed no dose-limiting toxicities across 42 patients and demonstrated a 57% objective response rate in Cohort 2, with seven of nine patients remaining progression-free beyond one year, highlighting a strong safety and efficacy profile.
The FDA granted Fast Track designation for VMT-α-NET in SSTR2-positive neuroendocrine tumors, potentially expediting regulatory review and accelerating time to market for the lead asset.
Perspective ended 2024 with $227 million in cash and equivalents, underwritten to fund planned operations and multiple clinical milestones into late 2026, supporting advancement of its diversified radiopharmaceutical pipeline without immediate capital raises
Perspective Therapeutics’ stock has plunged over 87% in the past year, reflecting significant downward pressure and eroded investor confidence amid clinical and market uncertainties.
Short interest in CATX has climbed to approximately 10.38% of the float, with a days-to-cover metric over 5, signaling bearish sentiment and potential persistent selling pressure.
The company reported only $0.37 million in quarterly revenue against a net margin of –4 096.66% and negative EPS, underscoring ongoing cash burn and raising dilution risk if additional financing is required
Data summarised monthly by Lightyear AI. Last updated on 17 Jul 2025.
CATX Financial Performance
Revenues and expenses
CATX Earnings Performance
Company profitability
CATX News
AllArticlesVideos
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
GlobeNewsWire·4 days ago
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
GlobeNewsWire·4 weeks ago
![Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fg%2Fw%2Fc%2Fpress3-3148314.jpg&w=3840&q=75)
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Perspective Therapeutics stock?
Perspective Therapeutics (CATX) has a market cap of $307M as of July 18, 2025.
What is the P/E ratio for Perspective Therapeutics stock?
The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of July 18, 2025.
Does Perspective Therapeutics stock pay dividends?
No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Perspective Therapeutics dividend payment date?
Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.
What is the beta indicator for Perspective Therapeutics?
Perspective Therapeutics (CATX) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.